Home  |  Blog  |  Press Statement  |  Statement on SMART Prices Act

Statement on SMART Prices Act

Chronic Care Policy Alliance (CCPA) released the below statement on SMART Prices Act:

“The Chronic Care Policy Alliance remains concerned about the impact of the Medicare Drug Price Negotiation Program on the future of new and ongoing research into new treatments for patients living with chronic diseases. In March, CCPA led 35 organizations in writing to the Administration and Congress to share our concerns. With implementation of the Medicare Drug Price Negotiation Program still getting underway, CCPA strongly believes that Congress should wait to see the impact of the program before expanding it. The potential impact on the development of new treatments for patients is of paramount concern – Congress should not expand the policy without having full information on the short-term and long-term effects of the policy. We urge Congress not to pursue S. 1264, the SMART Prices Act, nor H.R. 4895, the Lowering Drug Costs for American Families Act.” – Liz Helms, Founder | Director, Chronic Care Policy Alliance